非弁性心房細動の被験者における層流左心耳閉鎖システムの安全性と有効性を評価する早期実現可能性研究
This is an early feasibility study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation that cannot take, or a have a reason to seek an alternative, to anticoagulant medications.
調査の概要
詳細な説明
Left atrial appendage closure (LAAC) is an approved therapy for stroke prevention in atrial fibrillation patients who are recommended for chronic oral anticoagulation therapy (OAC), but are non-eligible or have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulants in accordance with evidence-based decision-making criteria and current scientific guidelines.
The objective of this study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation who are deemed appropriate for LAAC to reduce the risk of stroke and systemic embolism.
Patients will be followed for 5 years after the procedure.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85712
- Tucson Medical Center
-
-
Arkansas
-
Jonesboro、Arkansas、アメリカ、72401
- St. Bernard's Heart & Vascular
-
-
California
-
La Jolla、California、アメリカ、92037
- Scripps Health
-
Sacramento、California、アメリカ、95817
- Univeristy of California Davis Health
-
Thousand Oaks、California、アメリカ、91360
- Cardiovascular Institute Los Robles Hospital and Medical Center
-
-
New York
-
New York、New York、アメリカ、10032
- Columbia University Medical Center
-
New York、New York、アメリカ、10029
- Icahn School of Medicine at Mt. Sinai
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Documented non-valvular atrial fibrillation (AF), defined as AF (paroxysmal, persistent, or permanent) in the absence of moderate-to-severe mitral stenosis or a mechanical heart valve
- Participant greater than or equal to (>=)18 years old
- CHA2DS2-VASc score >=2 in men and >= 3 in women
- Participant is recommended for chronic oral anticoagulation therapy (OAC) but is not eligible or has an appropriate rationale to seek a non-pharmacologic alternative to chronic OAC
- Participant deemed appropriate for LAA closure by the Site Heart Team using an evidenced based decision-making tool
- Participant eligible for the protocol-specified post-procedural antithrombotic regimen
- Participant or Legally Authorized Representative informed of the nature of the study, is willing and able to comply with the protocol, and has provided written informed consent per Institutional Review Board (IRB) requirements
Exclusion Criteria:
- Single episode, transient, or reversible AF (for example, secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
- Stroke or transient ischemic attack within 90 days before the index procedure
- Myocardial infarction or unstable angina within 90 days before the index procedure
- Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) less than (<)30 milliliters per minute (mL/min)/1.73 sqaure meter (m^2), or dialysis at the time of screening
- Active infection with bacteremia
- Confirmed coronavirus disease 2019 (COVID-19) infection within 10 days before the index procedure Coexisting Cardiovascular Disease
- Cardiac tumor
- History of mitral valve or other severe cardiac valvular disease requiring intervention or presence of prosthetic mechanical valve
- Medical condition (other than AF) that mandates chronic oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or mechanical heart valve)
- Severe heart failure (New York Heart Association Class IV)
- Symptomatic carotid artery disease (greater than [>] 50 percent [%] diameter reduction with prior ipsilateral stroke or transient ischemic attack [TIA]) or asymptomatic carotid artery disease (diameter reduction of >70%) Previous or Planned Interventions
- Previous AF ablation procedure in the 90 days before the index procedure date or need for AF ablation to be performed in less than 90 days after the index procedure
- Recent (within 30 days before the index procedure) or planned (within 60 days after the index procedure) cardiac or non-cardiac interventional or surgical procedure
- Intracardiac thrombus or dense spontaneous echo contrast visualized by transesophageal echocardiographic (TEE) within 2 days before the index procedure
- Left ventricular ejection fraction (LVEF) <30%
- Circumferential pericardial effusion >10 mm or symptomatic pericardial effusion, signs or symptoms of acute or chronic pericarditis, or evidence of tamponade physiology
- Complex atheroma with mobile plaque of the aorta
- Interatrial communication, atrial septal defect, or patent foramen ovale that warrants closure
- Vascular access precluding delivery of implant with catheter-based system
- Presence of inferior vena cava (IVC) filter that would interfere with Laminar sheath insertion
- Participant unable to undergo general anesthesia
- Participant with condition which precludes adequate TEE assessment
- Known allergy, hypersensitivity or contraindication to aspirin, heparin, or device materials (e.g., nickel, titanium)
- Contrast sensitivity that cannot be adequately pre-medicated
- Thrombocytopenia , thrombocytosis, or leukopenia values as specified in protocol
- Pregnant or nursing and those who plan pregnancy in the period up to 1 year following the index procedure. Participants of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days before index procedure
- Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 1 year
- Current participation in another investigational drug or device study that in the opinion of the investigator could confound the data interpretation
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment
Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure system. |
Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite Adverse Events
時間枠:45 days
|
Composite rate of all-cause mortality, stroke, systemic embolism, life threatening or major bleeding (BARC Type 3 or 5), pericardial effusion requiring drainage, device embolization, and device- or procedure-related events requiring open cardiac surgery or major endovascular intervention. |
45 days
|
|
Composite Adverse Events
時間枠:12 months
|
Composite rate of all-cause mortality, stroke, systemic embolism, life threatening or major bleeding (BARC Type 3 or 5), pericardial effusion requiring drainage, device embolization, and device- or procedure-related events requiring open cardiac surgery or major endovascular intervention. |
12 months
|
|
LAA Closure Rate
時間枠:45 days
|
Rate of LAA closure defined by peri-device flow ≤ 3mm in width per TEE evaluated by independent core laboratory. |
45 days
|
|
LAA Closure Rate
時間枠:12 months
|
Rate of LAA closure defined by peri-device flow ≤ 3mm in width per TEE evaluated by independent core laboratory. |
12 months
|
|
LAA Closure Rate
時間枠:45 days
|
Rate of LAA closure per CCTA evaluated by independent core laboratory. Contrast patency defined as LAA density ≥100 HU or ≥25% of that of the left atrium. |
45 days
|
|
Composite of Ischemic Stroke or System Embolism
時間枠:12 months
|
Composite of ischemic stroke or systemic embolism. |
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Device-Related Thrombus
時間枠:45 days
|
Rate of device-related thrombus (DRT) per CCTA evaluated by independent core laboratory. |
45 days
|
|
Device-Related Thrombus
時間枠:12 months
|
Rate of DRT per TEE evaluated by independent core laboratory. |
12 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Biosense Webster, Inc. Clinical Trial、Biosense Webster, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CL0043
- LAM202404 (その他の識別子:Biosense Webster, Inc.)
- CL0043 (その他の識別子:Laminar, Inc.)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。